Narcolepsy in Parkinson’s disease

References

• Anders TF, Guilleminault C. The pathophysiology of sleep disorders in paediatrics. Part I. Sleep in infancy. Adv. Pediatr.22, 137–150 (1976).
   Google Scholar
• Guilleminault C, Anders TF. The pathophysiology of sleep disorders in paediatrics. Part II. Sleep disorders in children. Adv. Pediatr.22, 151–174 (1976).
   Google Scholar
• Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch. Neurol.31(4), 255–261 (1974).
   PubMedGoogle Scholar
• Beck B, Richy S. Hypothalamic hypocretin/orexin and neuropeptide Y: divergent interaction with energy depletion and leptin. Biochem. Biophys. Res. Commun.258, 119–122 (1999).
   PubMed Web of Science ®Google Scholar
• Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev.20, 68–100 (1999).
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci.24, 429–458 (2001).
   PubMed Web of Science ®Google Scholar
• Kilduff TS. Hypocretin/orexin: maintenance of wakefulness and a multiplicity of other roles. Sleep Med. Rev.9, 227–230 (2005).
   Google Scholar
• Kok SW, Meinders AE, Overeem S et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin-deficient narcoleptic humans. J. Clin. Endocrinol. Metab.87(2), 805–809 (2002).
   PubMed Web of Science ®Google Scholar
• Sakurai T. Physiological reviews: roles of hypocretin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med. Rev.9, 231–242 (2005).
   PubMed Web of Science ®Google Scholar
• Gulati A, Forbes A, Stegie F, Kelly L, Clough C, Chaudhuri KR. A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson’s disease ranging from early to advanced disease. Mov. Disord.19, S406 (2004).
   PubMedGoogle Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based prospective study. J. Am. Geriatr.48, 938–942 (2000).
   PubMed Web of Science ®Google Scholar
• Findley L, Aujila M, Bain PG et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov. Disord.18, 1139–1145 (2003).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy D, Schapira AHV. The non motor symptoms of Parkinson’s disease. Diagnosis and management. Lancet Neurol.5, 235–245 (2006).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, de Vos R, Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Baumann CR, Bassetti CL. Hypocretins (orexins) and sleep-wake disorders. Lancet10, 673–682 (2005).
   Google Scholar
• Aldrich MS. Diagnostic aspects of narcolepsy. Neurology50, S2–S7 (1998).
   Google Scholar
• Didato G, Nobili L. Treatment of narcolepsy. Expert Rev. Neurother.9(6), 897–910 (2009).
   PubMed Web of Science ®Google Scholar
• Britton TC. Chaudhuri KR. REM sleep behavior disorder and the risk of developing Parkinson disease or dementia. Neurology1472(15), 1294–1295 (2009).
   Google Scholar
• Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev.9, 185–200 (2005).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR. Nocturnal symptom complex in PD and its management. Neurology61(Suppl. 3), S17–S23 (2003).
   Google Scholar
• Garcia-Borreguero D, Larosa O, Bravo M. Parkinson’s disease and sleep. Sleep Med. Rev.7, 115–129 (2003).
   PubMed Web of Science ®Google Scholar
• Baumann CR, Bassetti CL. Hypocretins (orexins): clinical impact of the discovery of neurotransmitter. Sleep Med. Rev.9, 253–268 (2005).
   PubMed Web of Science ®Google Scholar
• Andreu N, Chale JJ, Senard JM, Thalamas C, Montastruc JI, Rascol O. l-DOPA induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin. Neuropharacol.22, 15–23 (1999).
   PubMedGoogle Scholar
• Frucht SJ, Rogers JD, Greene PE, Gordon MD, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52, 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks in Parkinson’s disease. Lancet355, 1333–1334 (2000).
   PubMed Web of Science ®Google Scholar
• R v Brian Thomas [2009] (Unreported, November 2009); R v Lowe [2005] (Unreported, March 2005, CC Manchester); R v Parks [1992] 2 S.C.R. 871.
   Google Scholar
• Gagnon JF, Bedard MA, Fantini ML et al. REM sleep behaviour disorder and REM sleep without atonia in Parkinson’s disease. Neurology59, 585–589 (2002).
   PubMed Web of Science ®Google Scholar
• Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology46(2), 388–393 (1996).
   PubMed Web of Science ®Google Scholar
• Arnulf I, Bonnet AM, Damier P et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology55, 281–288 (2000).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Luciano AL, Iacono D et al. HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson’s disease. Mov. Disord.18, 337–340 (2003).
   PubMedGoogle Scholar
• Benbir G, Ozekmekci S, Cinar M, Beskardes F, Apaydin H, Erginoz E. Features associated with the development of hallucinations in Parkinson’s disease. Acta Neurol. Scand.114, 239–243 (2006).
   Google Scholar
• Sakurai T, Moriguchi T, Furuya K et al. Structure and function of human prepro-hypocretin gene. J. Biol. Chem.274, 17771–17776 (1999).
   PubMedGoogle Scholar
• Gautvik KM, de Lecea L, Gautvik VT et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc. Natl Acad. Sci. USA93(16), 8733–8738 (1996).
   PubMed Web of Science ®Google Scholar
• de Lecea L, Kilduff TS, Peyron C et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA95, 322–327 (1998).
   PubMed Web of Science ®Google Scholar
• Peyron C, Tighe DK, Van den Pol AN et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci.18, 9996–10015 (1998).
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell698(3), 365–376 (1999).
   Google Scholar
• Mitler MM, Harsh J, Hirshkowitz M et al. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med.11(3), 231–243 (2000).
   Google Scholar
• Chemelli RM, Willie JT, Sinton CM et al. Narcolepsy in hypocretin knockout mice: molecular genetics of sleep regulation. Cell98, 437–451 (1999).
   PubMed Web of Science ®Google Scholar
• Espana RA, Baldo BA, Kelley AE, Berridge CW. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience106, 699–715 (2001).
   Google Scholar
• Hagan JJ, Leslie RA, Patel S et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl Acad. Sci. USA96, 10911–10916 (1999).
   PubMed Web of Science ®Google Scholar
• Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A. modulates the sleep–wake cycle of rats. Eur. J. Neurosci.12, 726–730 (2000).
   PubMed Web of Science ®Google Scholar
• Li Y, Gao XB, Sakurai T. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron – a potential mechanism for orchestrating the hypothalamic arousal system. Neuron36, 1169–1181 (2002).
   PubMed Web of Science ®Google Scholar
• Yamanaka A, Muraki Y, Tsujino N et al. Regulation of hypocretin neurons by the monoaminergic and cholinergic systems. Biochem. Biophys. Res. Commun.303, 120–129 (2003).
   Google Scholar
• Yang B, Sampson K, Ferguson AV. Excitatory effects of hypocretin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. J. Neurosci.23, 6215–6222 (2003).
   Google Scholar
• Mieda M, Wille JT, Hara J et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl Acad. Sci. USA101, 4649–4954 (2004).
   PubMed Web of Science ®Google Scholar
• Moore RY, Silver R. Suprachiasmatic nucleus organization. Chronobiol. Int.15, 475–487 (1998).
   PubMed Web of Science ®Google Scholar
• Saper C, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci.24, 726–731 (2001).
   PubMed Web of Science ®Google Scholar
• Korten JJ, Meulstee J. Olfactory disturbances in parkinsonism. Clin. Neurol. Neurosurg.82(2), 113–118 (1980).
   PubMedGoogle Scholar
• Singh S, Schwankhaus J. Olfactory disturbance in Parkinson disease. Arch. Neurol.66(6), 805 (2009).
   PubMedGoogle Scholar
• Abbott RD, Ross GW, White LR et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology65, 1442–1446 (2005).
   PubMed Web of Science ®Google Scholar
• Iranzo A, Molinuevo JL, Santamaria J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol.5, 572–577 (2006).
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S et al. Hypocretin deficiency in human narcolepsy. Lancet355, 39–40 (2000).
   PubMed Web of Science ®Google Scholar
• Mignot E, Lammers GJ, Ripley B et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol.59(10), 1553–1562 (2002).
   PubMed Web of Science ®Google Scholar
• Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy, and hypersomnia, and their implications in the hypothalamic hypocretin/hypocretin system. Sleep Med. Rev.9, 269–310 (2005).
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R et al. Reduced number of hypocretin peptides in human narcolepsy. Neuron27, 469–474 (2000).
   PubMed Web of Science ®Google Scholar
• Fronczek R, Baumann CR, Lammers GJ, Bassetti CL, Overeem S. Hypocretin/orexin disturbances in neurological disorders. Sleep Med. Rev.13, 9–22 (2009).
   Google Scholar
• Fronczek R, Overeem S, Lee SYY et al. Hypocretin (orexin) loss in Parkinson’s disease. Brain130, 1577–1585 (2007).
   PubMed Web of Science ®Google Scholar
• Gerashchenko D, Murillo-Rodriguez E, Lin L et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp. Neurol.184, 1010–1016 (2003).
   PubMed Web of Science ®Google Scholar
• Butkov N, Lee-Chiong TL (Eds). Fundamentals of Sleep Technology. Lipincott Williams & Wilkins, PA, USA 164 (2007).
   Google Scholar
• Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur. Neurol.52(2), 73–76 (2004).
   PubMed Web of Science ®Google Scholar
• Ripley B, Overeem S, Fujiki N et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology57, 2253–2258 (2001).
   PubMed Web of Science ®Google Scholar
• Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S, Lammers GJ. Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness. Neurology58, 498–499 (2002).
   Google Scholar
• Drouot X, Moutereau S, Nguyen JP et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology2661(4), 540–543 (2003).
   Google Scholar
• Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J. Neurosci.250, 120–123 (2006).
   Google Scholar
• Maeda T, Nagata K, Kondo H, Kanbayashi T. Parkinson’s disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level. Sleep Med.8, 662 (2006).
   Google Scholar
• Compta Y, Santamaria J, Ratti L et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson’s disease dementia. Brain132(Pt 12), 3308–3317 (2009).
   Web of Science ®Google Scholar
• Asai H, Hirano M, Furiya Y et al. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson’s disease. Clin. Neurol. Neurosurg.111, 341–344 (2009).
   Google Scholar
• Asai H, Hirano M, Furiya Y et al. Cerbrospinal fluid orexin levels and sleep attacks in four patients with Parkinson’s disease. Clin. Neurol. Neurosurg.11, 341–344 (2009).
   Google Scholar
• Thannickal TC, Lai Y-Y, Siegel J. Hypocretin and melanin concentrating hormone loss and the symptoms of Parkinson’s disease. Brain130, 1586–1595 (2007).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR. Logishetty K. Dopamine receptor agonists and sleep disturbances in Parkinson’s disease. Parkinsonism Relat. Disord.15S, S1–S4 (2009).
   Google Scholar